Patents by Inventor Antonio Concetti

Antonio Concetti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250332186
    Abstract: Provided herein are novel p62 compositions for the modulation of expression of a proinflammatory cytokines, osteogenic transcription factors, a bone resorptive factors and endogenous p62. Consequently, such p62 compositions are useful for prophylaxis and treatment of inflammatory diseases and related methods. In certain embodiments the inflammatory diseases are not cancer-related. In various embodiments, the inflammatory diseases include, but are not limited to osteoporosis, obesity, metabolic syndrome, type 2 diabetes, fat liver, inflammatory bowel disease, chronic pancreatitis, asthma, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis (RA), osteoarthritis, multiple sclerosis (MS), psoriasis, congestive heart failure (CHF), atherosclerosis, neurodegenerative diseases (ALS, Parkinson, Alzheimer's, Huntington disease), depression, schizophrenia, gout, asbestosis and silicosis.
    Type: Application
    Filed: April 30, 2024
    Publication date: October 30, 2025
    Inventors: Alexander Shneider, Franco Venanzi, Dimitrios Agas, Antonio Concetti, Maria Giovanna Sabbieti, Vladimir Gabai, Michael Sherman, Victor Shifrin
  • Publication number: 20220009985
    Abstract: Provided herein are novel p62 compositions for the modulation of expression of a proinflammatory cytokines, osteogenic transcription factors, a bone resorptive factors and endogenous p62. Consequently, such p62 compositions are useful for prophylaxis and treatment of inflammatory diseases and related methods. In certain embodiments the inflammatory diseases are not cancer-related. In various embodiments, the inflammatory diseases include, but are not limited to osteoporosis, obesity, metabolic syndrome, type 2 diabetes, fat liver, inflammatory bowel disease, chronic pancreatitis, asthma, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis (RA), osteoarthritis, multiple sclerosis (MS), psoriasis, congestive heart failure (CHF), atherosclerosis, neurodegenerative diseases (ALS, Parkinson, Alzheimer's, Huntington disease), depression, schizophrenia, gout, asbestosis and silicosis.
    Type: Application
    Filed: June 25, 2021
    Publication date: January 13, 2022
    Inventors: Alexander Shneider, Franco Venanzi, Dimitrios Agas, Antonio Concetti, Maria Giovanna Sabbieti, Vladimir Gabai, Michael Sherman, Victor Shifrin
  • Patent number: 11098098
    Abstract: Provided herein are novel p62 compositions for the modulation of expression of a proinflammatory cytokines, osteogenic transcription factors, a bone resorptive factors and endogenous p62. Consequently, such p62 compositions are useful for prophylaxis and treatment of inflammatory diseases and related methods. In certain embodiments the inflammatory diseases are not cancer-related. In various embodiments, the inflammatory diseases include, but are not limited to osteoporosis, obesity, metabolic syndrome, type 2 diabetes, fat liver, inflammatory bowel disease, chronic pancreatitis, asthma, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis (RA), osteoarthritis, multiple sclerosis (MS), psoriasis, congestive heart failure (CHF), atherosclerosis, neurodegenerative diseases (ALS, Parkinson, Alzheimer's, Huntington disease), depression, schizophrenia, gout, asbestosis and silicosis.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: August 24, 2021
    Assignee: CureLab Oncology, Inc.
    Inventors: Alexander Shneider, Franco Venanzi, Dimitrios Agas, Antonio Concetti, Maria Giovanna Sabbieti, Vladimir Gabai, Michael Sherman, Victor Shifrin
  • Publication number: 20190153056
    Abstract: Provided herein are novel p62 compositions for the modulation of expression of a proinflammatory cytokines, osteogenic transcription factors, a bone resorptive factors and endogenous p62. Consequently, such p62 compositions are useful for prophylaxis and treatment of inflammatory diseases and related methods. In certain embodiments the inflammatory diseases are not cancer-related. In various embodiments, the inflammatory diseases include, but are not limited to osteoporosis, obesity, metabolic syndrome, type 2 diabetes, fat liver, inflammatory bowel disease, chronic pancreatitis, asthma, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis (RA), osteoarthritis, multiple sclerosis (MS), psoriasis, congestive heart failure (CHF), atherosclerosis, neurodegenerative diseases (ALS, Parkinson, Alzheimer's, Huntington disease), depression, schizophrenia, gout, asbestosis and silicosis.
    Type: Application
    Filed: October 22, 2018
    Publication date: May 23, 2019
    Inventors: Alexander Shneider, Franco Venanzi, Dimitrios Agas, Antonio Concetti, Maria Giovanna Sabbieti, Vladimir Gabai, Michael Sherman, Victor Shifrin
  • Publication number: 20160324944
    Abstract: Provided herein are novel p62 compositions for the modulation of expression of a proinflammatory cytokines, osteogenic transcription factors, a bone resorptive factors and endogenous p62. Consequently, such p62 compositions are useful for prophylaxis and treatment of inflammatory diseases and related methods. In certain embodiments the inflammatory diseases are not cancer-related. In various embodiments, the inflammatory diseases include, but are not limited to osteoporosis, obesity, metabolic syndrome, type 2 diabetes, fat liver, inflammatory bowel disease, chronic pancreatitis, asthma, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis (RA), osteoarthritis, multiple sclerosis (MS), psoriasis, congestive heart failure (CHF), atherosclerosis, neurodegenerative diseases (ALS, Parkinson, Alzheimer's, Huntington disease), depression, schizophrenia, gout, asbestosis and silicosis.
    Type: Application
    Filed: December 29, 2014
    Publication date: November 10, 2016
    Inventors: Alexander Shneider, Franco Venanzi, Dimitrios Agas, Antonio Concetti, Maria Giovanna Sabbieti, Vladimir Gabai, Michael Sherman, Victor Shifrin
  • Publication number: 20090304728
    Abstract: The present invention relates to the modulation of a gene known as “tumor endothelial marker 8 (TEM8)” and refers to the differential levels with which the gene is expressed, in its variants, in cells exhibiting angiogenic and migratory properties such as dendritic cells and metastatic tumor cells. The present invention further relates to the use of gene and polypeptide sequences of TEM8 as instruments of diagnosis and prognosis of pathological inflammatory angiogenesis and of the metastatic potential of tumor cells. The invention further relates to the use of the same gene and polypeptide sequences as direct therapeutic instruments, and to the use in immunogenic compositions or in vaccines apt to induce an immune response against cells overexpressing TEM8 gene products. Furthermore, the present invention relates to screening methods for identifying agonists and antagonists of TEM8 activity in any polynucleotide and/or polypeptide variant thereof to be used in prevention or therapy treatments.
    Type: Application
    Filed: June 26, 2007
    Publication date: December 10, 2009
    Applicant: BIOSOOFT S.R.L.
    Inventors: Antonio Concetti, Franco M. Venanzi
  • Publication number: 20080171058
    Abstract: The present invention discloses a synergistic effect between vaccines encoding tumor-associated antigen and vaccines encoding tumor endothelial marker (8) (TEM8). Potent antitumor immunity was generated by the combined use of these vaccines. Tumor supported by vasculature and for which a tumor-associated antigen has been defined can be treated with this approach.
    Type: Application
    Filed: November 15, 2004
    Publication date: July 17, 2008
    Inventors: Polly Gregor, Alan Houghton, Franco M. Venanzi, Antonio Concetti
  • Patent number: 6127344
    Abstract: Polynucleotide immunogenic agents capable of inducing an immune response towards the members of the Epidermal Growth Factor Receptors (EGFR) family are disclosed.
    Type: Grant
    Filed: November 25, 1997
    Date of Patent: October 3, 2000
    Assignee: Universita' Degli Studi di Camerino
    Inventors: Augusto Amici, Antonio Concetti, Franco Venanzi